According to a regulatory filing, in November 2022, Abbott learned that the United States Department of Justice, through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of infant formula. In December 2022, Abbott received a subpoena from the Enforcement Division of the Commission requesting information relating to Abbott’s powder infant formula business and related public disclosures. In January 2023, Abbott received a civil investigative demand from the United States Federal Trade Commission seeking information in connection with its investigation of companies who participate in bids for Women, Infants, and Children infant formula contracts. In addition, multiple civil lawsuits have been filed against Abbott regarding Abbott’s manufacturing of certain powder infant formula products.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott Declares 397th Consecutive Quarterly Dividend
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Cardiovascular Systems downgraded to Sell from Buy at Lake Street
- Abbott (ABT) Trying to Lift Sales With $890M Buyout
- Cardiovascular Systems jumps 43% after announcing it is being acquired by Abbott
